NovaBridge Biosciences (NBP) Current Deferred Revenue (2018 - 2023)

NovaBridge Biosciences (NBP) has 5 years of Current Deferred Revenue data on file, last reported at $305552.3 in Q4 2023.

• Current Deferred Revenue for Q4 2023 came in at $305552.3, down 74.96% year-over-year; the trailing twelve-month figure through Dec 2023 was $305552.3 (down 74.96% YoY), and the FY2023 annual result was $600000.0, down 99.95% from the prior year.
• Current Deferred Revenue eased to $305552.3 in Q4 2023 per NBP's latest filing, from $1.5 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $8.2 million in Q2 2022 and troughed at -$2.0 million in Q3 2019.
• A 4-year average of $1.7 million and a median of $1.2 million in 2020 frame the typical range for Current Deferred Revenue.
• On a YoY basis, Current Deferred Revenue climbed as much as 74.96% in 2023 and fell as far as 82.24% in 2023.
• A 4-year view of Current Deferred Revenue shows it stood at -$2.0 million in 2019, then jumped by 156.12% to $1.1 million in 2020, then grew by 7.68% to $1.2 million in 2022, then sank by 74.96% to $305552.3 in 2023.
• Business Quant data shows NBP's Current Deferred Revenue at $305552.3 in Q4 2023, $1.5 million in Q2 2023, and $1.2 million in Q4 2022.